Today: 10 June 2026
Browse Category

NASDAQ:MIST 12 December 2025 - 15 December 2025

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray for adults with paroxysmal supraventricular tachycardia, marking the first new U.S. PSVT treatment in over 30 years. The company targets retail availability in Q1 2026. Shares showed sharp volatility after the announcement. Milestone scheduled an investor call for December 15 to discuss launch plans.
15 December 2025
·
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals said late Friday the FDA approved CARDAMYST (etripamil) as the first self-administered nasal spray for PSVT. MIST shares closed down 18.3% at $2.41 after volatile trading and heavy volume, but rebounded modestly after hours. CARDAMYST is expected in pharmacies in Q1 2026. In a Phase 3 trial, 64% of patients converted to normal rhythm within 30 minutes, compared to 31% on placebo.
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST nasal spray for on-demand treatment of PSVT in adults, marking the first new U.S. therapy for the condition in over 30 years. The company expects CARDAMYST in pharmacies by Q1 2026. MIST shares were volatile ahead of the decision and ended the week lower despite the approval.
13 December 2025
··
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals shares closed at $2.95 on Dec. 11, up 10.49% with about 7.54 million shares traded, ahead of an FDA decision on CARDAMYST nasal spray for PSVT due Dec. 13. The stock traded around $2.98 pre-market Dec. 12, rebounding from a 52-week low of $0.625 after an FDA rejection earlier in 2025 and subsequent resubmission.
12 December 2025
·

Stock Market Today

  • Neelamalai Agro Industries' Earnings Boosted by Unusual Items, Raising Caution
    June 9, 2026, 8:48 PM EDT. Neelamalai Agro Industries (NSE:NEAGI) reported strong profits with earnings per share up 26%, but its stock remained stagnant amid concerns over an ₹8.0 million boost from unusual items. Such non-recurring gains, by definition, can distort true profitability and may not recur, raising caution among investors. Analysts warn that underlying earnings power could be less than statutory profit suggests. Additionally, five warning signs have been identified for NEAGI, with two flagged as significant risks. Investors are advised to review balance sheet strength and conduct thorough risk assessments before investing. The case exemplifies the complexity behind valuation amid one-off profit boosts, highlighting the need for deeper financial scrutiny beyond headline figures.

Latest articles

Nasdaq Sees More Moves After Hours Following U.S. Strike on Iran

Nasdaq Sees More Moves After Hours Following U.S. Strike on Iran

10 June 2026
U.S. stock futures fell after hours and oil rose as U.S. strikes on Iran fueled risk-off sentiment, deepening losses in tech shares and raising investor caution ahead of Wednesday’s key inflation report, with fears of Fed rate hikes and volatility from the upcoming SpaceX IPO adding pressure.
Keel Slides After $458 Million AI Data-Center Debt Deal Launch

Keel Slides After $458 Million AI Data-Center Debt Deal Launch

10 June 2026
Keel Infrastructure shares plunged 4.24% to $5.42 after closing a $458 million convertible debt sale, reviving investor fears of future dilution even as the company boosts funding for AI-focused data-center projects; shares slipped further to $5.32 after hours on more than double average volume, reflecting concerns over execution risks and the impact of new financing.
Super Micro sinks after $7B AI server plan; dilution a risk

Super Micro sinks after $7B AI server plan; dilution a risk

10 June 2026
Super Micro Computer plans to raise $7 billion through equity and equity-linked financing to fund soaring AI server orders, sending shares down about 9% in after-hours trading as investors focused on dilution risk; the company reported $39 billion in recent AI server orders, but noted these are not firm commitments and cited ongoing legal and regulatory risks.
American Airlines Stock Rises on Google Fuel Deal, Market Watches for Fuel Shock

American Airlines Stock Rises on Google Fuel Deal, Market Watches for Fuel Shock

10 June 2026
American Airlines surged to $14.09, up 48.5 cents, after announcing a three-year sustainable aviation fuel deal with Google covering 35 million gallons, as investors focused on surging fuel costs that jumped 78% in April to $6.5 billion; the stock rose in line with airline peers amid a drop in crude prices, while American’s 2026 outlook remains pressured by higher fuel expenses and a narrowed profit forecast.
Nokia Drops 7% After Nvidia 6G Chatter Hits AI Stocks

Nokia Drops 7% After Nvidia 6G Chatter Hits AI Stocks

10 June 2026
Nokia shares plunged 6.99% to 11.970 euros in Helsinki after reports of Nvidia’s push into future mobile-network tech raised fears over Nokia’s AI-driven growth story, with investors questioning whether Nokia can maintain its edge as competition intensifies and its forward P/E more than doubles this year.
Go toTop